

Available online at www.sciencedirect.com

SciVerse ScienceDirect

journal homepage: www.elsevier.com/locate/crvasa

Guidelines

Third universal definition of myocardial infarction [☆]



Jan Vojáček^{a,*}, Petr Janský^b, Tomáš Janota^c

^aDepartment of Cardiovascular Medicine I, University Hospital Hradec Kralove, Czech Republic

^bDepartment of Cardiovascular Surgery, University Hospital Motol, Prague, Czech Republic

^cCardio ICU, 3rd Department of Internal Medicine University Hospital, Charles University, Prague, Czech Republic

Authors of the original ESC update document [1]: Kristian Thygesen, Joseph S. Alpert on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction.

ARTICLE INFO

Article history:

Received 6 December 2012

Accepted 16 December 2012

Available online 3 January 2013

Keywords:

Myocardial infarction

Definition



EUROPEAN
SOCIETY OF
CARDIOLOGY®



ČESKÁ KARDIOLOGICKÁ SPOLEČNOST
THE CZECH SOCIETY OF CARDIOLOGY

Contents

1. Preamble	229
2. Introduction	229
2.1. What is new in the third universal definition of myocardial infarction.	229
2.1.1. Definition of myocardial infarction	229
2.1.2. Pathological characteristics of myocardial ischaemia and infarction	229
2.1.3. Biomarker detection of myocardial injury with necrosis.	229
2.1.4. Clinical features of myocardial ischaemia and infarction	231
3. Clinical classification of myocardial infarction.	231
3.1. Spontaneous myocardial infarction (MI type 1).	231
3.2. Myocardial infarction secondary to an ischaemic imbalance (MI type 2).	231
3.3. Cardiac death due to myocardial infarction (MI type 3)	231
3.4. Myocardial infarction associated with revascularization procedures (MI types 4 and 5)	231

[☆]For permissions: please e-mail: guidelines@escardio.org.

*Corresponding author.

E-mail address: vojacjan@fnhk.cz (J. Vojáček).

3.5.	Diagnostic criteria for myocardial infarction with PCI (MI type 4)	232
3.6.	Diagnostic criteria for myocardial infarction with CABG (MI type 5)	232
3.7.	Assessment of MI in patients undergoing other cardiac procedures	232
3.8.	Myocardial infarction associated with non-cardiac procedures	232
3.9.	Myocardial infarction in the intensive care unit	233
3.10.	Myocardial injury or infarction associated with heart failure	233
4.	Electrocardiographic detection of myocardial infarction	233
4.1.	Prior myocardial infarction	234
4.2.	ECG changes associated with prior myocardial infarction.	234
4.3.	Conditions that confound the ECG diagnosis of myocardial infarction	234
5.	Imaging techniques	234
5.1.	Echocardiography	234
5.2.	Radionuclide imaging	234
5.3.	Magnetic resonance imaging	234
5.4.	Computed tomography	235
5.5.	Applying imaging in acute myocardial infarction	235
5.6.	Applying imaging in late presentation of myocardial infarction	235
6.	Incident and recurrent myocardial infarction, reinfarction	235
	Reference	235

1. Preamble

The ESC guidelines help physicians to make decisions in their practice, but do not override the responsibility of health professionals to make decisions and to follow the rules and regulations applicable to drugs and devices.

2. Introduction

In 2000, the First Global MI Task Force presented a new definition of MI, which implied that any necrosis in the setting of myocardial ischaemia should be labelled as MI. These principles were further refined by the Second Global MI Task Force, leading to the Universal Definition of Myocardial Infarction Consensus Document in 2007, which emphasized the different conditions which might lead to an MI. However, the development of even more sensitive assays for markers of myocardial necrosis mandates further revision, particularly when such necrosis occurs in the setting of the critically ill, after percutaneous coronary procedures or after cardiac surgery. The Third Global MI Task Force has continued the Joint ESC/ACCF/AHA/WHF efforts by integrating these insights and new data into the current document, which now recognizes that very small amounts of myocardial injury or necrosis can be detected by biochemical markers and/or imaging.

2.1. What is new in the third universal definition of myocardial infarction

- Criteria for an acute myocardial infarction: new identification of intracoronary thrombus by angiography or autopsy.
- Elevation of cardiac troponin values because of myocardial injury:
 - myocardial injury related to primary myocardial ischaemia (MI type I);
 - myocardial injury related to supply/demand imbalance (MI type II);
 - myocardial injury not related to myocardial ischaemia.

- New multifactorial or undetermined myocardial injury (heart failure, stress Tako-tsubo cardiomyopathy, severe pulmonary embolism or hypertension, sepsis and critically ill patients, renal failure, severe acute neurological diseases e.g. stroke, subarachnoid haemorrhage, infiltrative disease, e.g. amyloidosis, sarcoidosis, strenuous exercise).
- ECG criteria of ST elevation *age and gender specific*.
- Criteria for periprocedural MI.

2.1.1. Definition of myocardial infarction

Definition of myocardial infarction is given in [Table 1](#).

2.1.2. Pathological characteristics of myocardial ischaemia and infarction

MI is defined in pathology as *myocardial cell death due to prolonged myocardial ischaemia*. After the onset of myocardial ischaemia, histological cell death is not immediate, but takes a finite period of time to develop—as little as 20 min—or less in some animal models. It takes several hours before myocardial necrosis can be identified by macroscopic or microscopic post-mortem examination. Complete necrosis of myocardial cells at risk requires at least 2–4 h, or longer, depending on the presence of collateral circulation to the ischaemic zone, persistent or intermittent coronary arterial occlusion, the sensitivity of the myocytes to ischaemia, preconditioning, and individual demand for oxygen and nutrients. The entire process leading to a healed infarction usually takes at least 5–6 weeks. Reperfusion may alter the macroscopic and microscopic appearance.

2.1.3. Biomarker detection of myocardial injury with necrosis

Myocardial injury is detected when blood levels of sensitive and specific biomarkers such as cTn or the MB fraction of creatine kinase (CKMB) are increased. Cardiac troponin I and T are components of the contractile apparatus of myocardial cells and are expressed almost exclusively in the heart. Although elevations of these biomarkers in the blood reflect injury leading to necrosis of myocardial cells, they do not indicate the

Download English Version:

<https://daneshyari.com/en/article/5879899>

Download Persian Version:

<https://daneshyari.com/article/5879899>

[Daneshyari.com](https://daneshyari.com)